Let #39;s Play: The Sims 3 Pets - (Part 34) - Equestrian Genetics
HIGHLIGHTS: -Julie #39;s midlife crisis ends! (thank god.. -We get lifetime happiness rewards! -Queen gets to level 9 in racing! -Granny learns the handiness ski...

By: SoulSimmer

Go here to see the original:
Let's Play: The Sims 3 Pets - (Part 34) - Equestrian Genetics - Video

Recommendation and review posted by Bethany Smith

Cannabis Genetics History EXODUS CHEESE grown by Lady Sativa Genetics Amsterdam Weed Review
visit http://andrew.pyrah.net for more - COMMENT and LIKE if you enjoyed the video and SUBSCRIBE to see my new videos as they are released - it all helps my ...

By: Andrew Pyrah

The rest is here:
Cannabis Genetics & History EXODUS CHEESE grown by Lady Sativa Genetics Amsterdam Weed Review - Video

Recommendation and review posted by Bethany Smith

The Sims 3 Perfect Genetics Challenge (Part 1) Welcome!
OPEN FOR IMPORTANT LINKS AND INFO Like/Follow me on: ONLINE STORE: http://jessamica92.spreadshirt.com/ SECOND CHANNEL: http://www.youtube.com/user/JessaGames WEBSITE: http://www.jessamica...

By: jessamica92

See the article here:
The Sims 3 Perfect Genetics Challenge (Part 1) Welcome! - Video

Recommendation and review posted by Bethany Smith

Biotechnology - GMO #39;s Gene Therapy
Video notes on genetically modified organisms gene therapy.

By: vancebiology

See the original post:
Biotechnology - GMO's & Gene Therapy - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

1-May-2014

Contact: Leslie Orr Leslie_Orr@urmc.rochester.edu University of Rochester Medical Center

University of Rochester scientists have discovered a gene with a critical link to pancreatic cancer, and further investigation in mice shows that by blocking the gene's most important function, researchers can slow the disease and extend survival.

Published online by Cell Reports, the finding offers a potential new route to intrude on a cancer that usually strikes quickly, has been stubbornly resistant to targeted therapies, and has a low survival rate. Most recent improvements in the treatment of pancreatic cancer, in fact, are the result of using different combinations of older chemotherapy drugs. The research led by Hartmut "Hucky" Land, Ph.D., and Aram F. Hezel, M.D., of UR Medicine's James P. Wilmot Cancer Center, identifies a new target in the process of garbage recycling that occurs within the cancer cell called autophagy, which is critical to pancreatic cancer progression and growth.

Autophagy is derived from the Greek roots "auto" (self) and "phagein" (to eat), and is an intracellular digestive process that allows cells to survive under stress. During a cell's transformation from normal to malignant, autophagy speeds up to keep pace with rapid cellular changes and a tumor's quest to grow. The newly discovered PLAC-8 gene sustains the highly active recycling process, as it removes faulty proteins and organelles and degrades them into reusable building blocks during cancer progression.

"What makes this an exciting opportunity is that the gene we're studying is critical to the cancer cell's machinery but it is not essential to the function of normal cells," said Land, chair of Biomedical Genetics at the University of Rochester School of Medicine and Dentistry and director of research at Wilmot. "By targeting these types of non-mutated genes that are highly specific to cancer, we are looking for more effective ways to intervene."

The Cell Reports study underlines Wilmot's overall unique approach to cancer research. Rather than investigate single faulty genes linked to single subtypes of cancer, Rochester scientists have identified a larger network of approximately 100 non-mutated genes that cooperate and control the shared activities of many cancers. While investigating this larger gene network, Land and Hezel focused on PLAC-8.

Moreover, the team found that by inactivating PLAC-8 in mice and shutting down autophagy, they could significantly slow cancer's progression. The relevance of PLAC-8 may also extend to other tumors lung, colon, and liver, for example -- that share key genetic changes such as KRAS and p53 mutations that are present in the majority of pancreatic cancers. The breadth of these findings is an area of ongoing study in the Land and Hezel labs.

"PLAC-8 and its job within the cancer cell of accelerating recycling suggests new points of attack and what we all hope will be opportunities to identify and develop new treatments," said Hezel, vice chief of Wilmot's Division of Hematology and Oncology and a UR associate professor. "Our data showing PLAC 8's role in autophagy has great potential because while there are other drugs being evaluated to inhibit autophagy, not all of them target proteins specifically important to this process in tumors."

Read more:
Gene discovery links cancer cell 'recycling' system to potential new therapy

Recommendation and review posted by Bethany Smith

NSC 342 Spinal Cord Injury Group Project
Daemen College, NSC 342 Spring 2014 Group Project Bailey Crook Katie Bull Nicole Kelley Sarah Munella.

By: smileeeitssarah

Read the original:
NSC 342 Spinal Cord Injury Group Project - Video

Recommendation and review posted by sam

Heart cells created from human embryonic stem cells successfully restored damaged heart muscles in monkeys.

The results of the experiment appear in the April 30 advanced online edition of the journal Nature in a paper titled, "Human embryonic-stem cell derived cardiomyocytes regenerate non-human primate hearts."

The findings suggest that the approach should be feasible in humans, the researchers said.

"Before this study, it was not known if it is possible to produce sufficient numbers of these cells and successfully use them to remuscularize damaged hearts in a large animal whose heart size and physiology is similar to that of the human heart," said Dr. Charles Murry, UW professor of pathology and bioengineering, who led the research team that conducted the experiment.

A physician/scientist, Murry directs the UW Center for Cardiovascular Biology and is a UW Medicine pathologist.

Murry said he expected the approach could be ready for clinical trials in humans within four years.

In the study, Murry, along with Dr. Michael Laflamme and other colleagues at the UW Institute for Stem Cell & Regenerative Medicine, experimentally induced controlled myocardial infarctions, a form of heart attack, in anesthetized pigtail macaques.

The infarcts were created by blocking the coronary artery of macaque for 90 minutes, an established model for the study of myocardial infarction in primates.

In humans, myocardial infarctions are typically caused by coronary artery disease. The resulting lack of adequate blood flow can damage heart muscle and other tissues by depriving them of oxygen. Because the infarcted heart muscle does not grow back, myocardial infarction leaves the heart less able to pump blood and often leads to heart failure, a leading cause of cardiovascular death.

The goal of stem cell therapy is to replace the damaged tissue with new heart cells and restore the failing heart to normal function.

Continued here:
Stem cell therapy regenerates heart muscle damaged from heart attacks in primates

Recommendation and review posted by simmons

Spinal Cord Injury Standing
April 27 2014 Me Practacing standing. A bit scary but I think it will get better. Doing it is key.

By: Ian Sands

Read more from the original source:
Spinal Cord Injury Standing - Video

Recommendation and review posted by sam

Trigger Point Injections to manage pain of Arachnoiditis (spinal cord injury)
Arachnoiditis Survivor needs your help to raise awareness include other Survivors in an empowering art project. This update posted for the Arachnoiditis Su...

By: Sheila Kalkbrenner

More:
Trigger Point Injections to manage pain of Arachnoiditis (spinal cord injury) - Video

Recommendation and review posted by sam

Malaysia to open new budget airport in MH370 shadow

Sepang (Malaysia) (AFP) - Malaysia this week opens what it calls the world's largest airport built specifically for low-cost airlines, a project driven by budget travel's phenomenal growth but which debuts under the shadow of missing flight MH370. The $1.2 billion facility near the main Kuala Lumpur International Airport (KLIA) was originally targeted to open three years ago but has been hit by repeated delays, amid concerns over safety and subpar construction, even as costs have doubled. But the new KLIA2 budget terminal will begin operations Friday with an initial 56 flights, increasing the load as airlines move full operations over from a nearby existing facility in coming days. Its modern design features soaring ceilings, natural lighting, people-mover belts and improved connectivity with access to an existing express airport train to Kuala Lumpur 50 kilometres (31 miles) away.

Excerpt from:
Stem cell heart repair study hailed

Recommendation and review posted by Bethany Smith

Apr 29, 2014 Marbled Salamander, Ambystoma opacum. Location: Durham County, North Carolina, United States. Photograph by Patrick Coin, via Wikipedia.

Imagine filling a hole in your heart by regrowing the tissue. While that possibility is still being explored in people, it is a reality in salamanders. A recent discovery that newt hearts can regenerate may pave the way to new therapies in people who need to have damaged tissue replaced with healthy tissue.

Heart disease is the leading cause of deaths in the United States. Preventative measures like healthful diets and lifestyles help ward off heart problems, but if heart damage does occur, sophisticated treatments and surgical procedures often are necessary. Unfortunately, heart damage is typically irreversible, which is why researchers are seeking regenerative therapies that restore a damaged heart to its original capacity.

We have known for hundreds of years that newts and other types of salamanders regenerate limbs. If you cut off a leg or tail, it will grow back within a few weeks. Stanley Sessions, a researcher at Hartwich College in Oneonta, N.Y., wondered if this external phenomenon also took place internally. To find out, he surgically removed a piece of heart in more than two dozen newts.

"To our surprise, if you surgically remove part of the heart, (the creature) will regenerate a new heart within just six weeks or so," Sessions said. "In fact, you can remove up to half of the heart, and it will still regenerate completely!"

Before the research team dove deeper into this finding, Sessions and his three undergraduate students, Grace Mele, Jessica Rodriquez and Kayla Murphy, had to determine how a salamander could even live with a partial heart. It turns out that a clot forms at the surgical site, acting much like the cork in a wine bottle, to prevent the amphibian from bleeding to death.

What is the cork made of? In part, stem cells. Stem cells have unlimited potential for growth and can develop into cells with a specialized fate or function. Embryonic stem cells, for example, can give rise to all of the cells in the body and, thus, have promising potential for therapeutics.

As it turns out, stem cells play an important role in regeneration in newts. "We discovered that at least some of the stem cells for heart regeneration come from the blood, including the clot," Sessions explained.

This finding could have exciting implications for therapies in humans with heart damage. By finding the genes responsible for regeneration in the newt, researchers may be able to identify pathways that are similar in newts and people and could be used to induce regeneration in the human heart. In fact, a clinical trial performed just last year was the first to use stem-cell therapy to regenerate healthy tissue and repair a patient's heart.

Combining advances in medical and surgical technologies with the basic pathways of heart regeneration in newts could lead to better therapies for humans. Sessions posed this hopeful question: "Wouldn't it be great if we could find a way to activate heart stem cells to bioengineer new heart tissue so that we can actually repair damaged hearts in humans?"

The rest is here:
Stem cells aid heart regeneration in salamanders

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise New York, NYApril 30, 2014Researchers at Columbia Engineering announced today that they have successfully grown fully functional human cartilage in vitro from human stem cells derived from bone marrow tissue. Their study, which demonstrates new ways to better mimic the enormous complexity of tissue development, regeneration, and disease, is published in the April 28 Early Online edition of Proceedings of the National Academy of Sciences (PNAS).

Weve been ablefor the first timeto generate fully functional human cartilage from mesenchymal stem cells by mimicking in vitro the developmental process of mesenchymal condensation, says Gordana Vunjak-Novakovic, who led the study and is the Mikati Foundation Professor of Biomedical Engineering at Columbia Engineering and professor of medical sciences. This could have clinical impact, as this cartilage can be used to repair a cartilage defect, or in combination with bone in a composite graft grown in lab for more complex tissue reconstruction.

For more than 20 years, researchers have unofficially called cartilage the official tissue of tissue engineering, Vunjak-Novakovic observes. Many groups studied cartilage as an apparently simple tissue: one single cell type, no blood vessels or nerves, a tissue built for bearing loads while protecting bone ends in the joints. While there has been great success in engineering pieces of cartilage using young animal cells, no one has, until now, been able to reproduce these results using adult human stem cells from bone marrow or fat, the most practical stem cell source. Vunjak-Novakovics team succeeded in growing cartilage with physiologic architecture and strength by radically changing the tissue-engineering approach.

The general approach to cartilage tissue engineering has been to place cells into a hydrogel and culture them in the presence of nutrients and growth factors and sometimes also mechanical loading. But using this technique with adult human stem cells has invariably produced mechanically weak cartilage. So Vunjak-Novakovic and her team, who have had a longstanding interest in skeletal tissue engineering, wondered if a method resembling the normal development of the skeleton could lead to a higher quality of cartilage.

Sarindr Bhumiratana, postdoctoral fellow in Vunjak-Novakovics Laboratory for Stem Cells and Tissue Engineering, came up with a new approach: inducing the mesenchymal stem cells to undergo a condensation stage as they do in the body before starting to make cartilage. He discovered that this simple but major departure from how things were usually? being done resulted in a quality of human cartilage not seen before.

Gerard Ateshian, Andrew Walz Professor of Mechanical Engineering, professor of biomedical engineering, and chair of the Department of Mechanical Engineering, and his PhD student, Sevan Oungoulian, helped perform measurements showing that the lubricative property and compressive strengththe two important functional propertiesof the tissue-engineered cartilage approached those of native cartilage. The researchers then used their method to regenerate large pieces of anatomically shaped and mechanically strong cartilage over the bone, and to repair defects in cartilage.

Our whole approach to tissue engineering is biomimetic in nature, which means that our engineering designs are defined by biological principles, Vunjak-Novakovic notes. This approach has been effective in improving the quality of many engineered tissuesfrom bone to heart. Still, we were really surprised to see that our cartilage, grown by mimicking some aspects of biological development, was as strong as normal human cartilage.

The team plans next to test whether the engineered cartilage tissue maintains its structure and long-term function when implanted into a defect.

See the article here:
Columbia Engineers Grow Functional Human Cartilage in Lab

Recommendation and review posted by Bethany Smith

Written by Lidia Dinkova on April 30, 2014

After 15 years of University of Miami research on a unique adult bone marrow-derived stem cell and on a process that leaves the cell in a relatively pure form, the university and its tissue bank have partnered with a Marietta, GA, biomedical company to make the stem cell called the MIAMI cell commercially available in July.

Vivex Biomedical Inc. invested in the research and development of the cell and licensed the technology from UM for orthopedic use, said company President and CEO Tracy S. Anderson. Vivex has contracted with the universitys tissue bank to develop the cell for commercial use. The company will pay an undisclosed royalty to UM from sales.

Dr. H. Thomas Temple, professor of orthopedics, vice chair of orthopedic surgery and director of the University of Miami Tissue Bank, said South Florida is a viable market for the MIAMI cell.

Just in bone [regeneration] alone theres an enormous market, and then if you take into consideration all the joint dysfunction that occurs with aging we have a significantly aged population, he said. If you think about the number of trauma cases we have down here where patients have open fractures, I think this has enormous potential.

Not a lot of companies, Dr. Temple said, are keen on investing in stem cells.

A lot of big companies dont want to take the risk on stem cells because they dont understand it, and theyre making a lot of money on other things, he said. The university doesnt have the financial resources to do the development work. They [UM] do a great job of investigating and researching these things, but the development side takes a lot of capital. In order to have a successful product, not only does it have to be really good, you have to have a successful market, so they [Vivex] bring in the distribution.

The marrow-isolated adult multi-lineage inducible cell, or MIAMI cell, is unique on two fronts. Its highly inducible and potent partially because it shares genes with embryonic stem cells, and the process used to isolate it allows for the infusion of a purer MIAMI cell concentration.

Generally in other processes, when stem cells are infused, they come with other cells that may be synergistic but more likely antagonistic, Dr. Temple said.

Its a small percentage of that actual layer that are actually stem cells. It may be effective, but this is different, he said. When we provide the cells, we can tell you that 95% of them are really MIAMI cells. Once theyre thawed, 97% to 98% of them are viable. Its really the process that makes them different.

Go here to read the rest:
UM research lands stem cell deal

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

30-Apr-2014

Contact: Deborah Williams-Hedges debwms@caltech.edu 626-395-3227 Landes Bioscience

A gene known to repair DNA damage in healthy cells may also provide new insights about treating a genetic disorder of the bone marrow, Caltech researchers say.

This finding was published in the May 15 print edition of the journal Cell Cycle.

In the study led by Judith Campbell, professor of chemistry and biology at Caltech, the researchers investigated the relationship between two genesFANCD2 and DNA2both known to play roles in fixing broken or damaged strands of DNA within a cell, called DNA repair. A defective version of the FANCD2 gene can result in the genetic disease Fanconi anemia (FA), which is characterized by failure of the bone marrow (an inability to replenish the body's supply of blood cells) and a predisposition to certain developmental disorders and cancers. Although DNA2 has not been associated with an FA family as yet, genetic studies implicate DNA2 in the FA DNA repair pathway.

To determine the relationship between the genes, the researchers applied formaldehyde and other DNA-damaging substances to three types of cells: those lacking FANCD2, those lacking DNA2, and cells lacking both FANCD2 and DNA2. The groups of cells in which only one of the two genes had been deleted quickly succumbed to the formaldehyde-induced DNA damage; however, the cells lacking both FANCD2 and DNA2 were able to repair the DNA damage and survive.

"A key implication of this finding is the potential to manipulate DNA2 to improve the survival of FANCD2-deficient cells, and hopefully, by extension, the survival of FA patients," says Kenneth Karanja, a former postdoctoral scholar in Campbell's laboratory and first author on the study. Currently, the only treatment for FA is a bone marrow transplant, but even after the transplant the disease remains lethal.

"DNA2 is a well-studied gene, and this recent discovery could potentially become the basis for ameliorating the symptoms of this incurable disorder," Campbell says. Furthermore, she says, the protein DNA2 encodes is a nucleasewhich is a specific type of enzyme that has become a promising drug target.

"Since much is known about the mechanism of action of DNA2, it is an attractive target for future drug treatmentslike small-molecule inhibitors that could reduce an FA patient's cancer predispositionas well as a possible gene therapy for aiding a patient's blood cell development," she says.

Original post:
DNA repair gene provides new ideas for disease treatment

Recommendation and review posted by Bethany Smith

Malaysia to open new budget airport in MH370 shadow

Sepang (Malaysia) (AFP) - Malaysia this week opens what it calls the world's largest airport built specifically for low-cost airlines, a project driven by budget travel's phenomenal growth but which debuts under the shadow of missing flight MH370. The $1.2 billion facility near the main Kuala Lumpur International Airport (KLIA) was originally targeted to open three years ago but has been hit by repeated delays, amid concerns over safety and subpar construction, even as costs have doubled. But the new KLIA2 budget terminal will begin operations Friday with an initial 56 flights, increasing the load as airlines move full operations over from a nearby existing facility in coming days. Its modern design features soaring ceilings, natural lighting, people-mover belts and improved connectivity with access to an existing express airport train to Kuala Lumpur 50 kilometres (31 miles) away.

Read the rest here:
Stem Cells Made Using Human Cloning Technique 'Hold Potential Cure for Diabetes'

Recommendation and review posted by Bethany Smith

Stem cell therapy | irish stem cells
http://www.arthritistreatmentcenter.com So what #39;s going on in Ireland when it comes to arthritis... coming up next... First signs of arthritis cure seen by Irish researchers The first signs...

By: Nathan Wei

See the rest here:
Stem cell therapy | irish stem cells - Video

Recommendation and review posted by Bethany Smith

Stem Cell Treatment In Panama Working Wonders
This is an update on Beverly after only 10 days in Panama for Stem Cell Treatment. She is feeling so much better and you can see it just by the look on her face. She has Secondary Progressive...

By: Stem Cell Patient

Read the original:
Stem Cell Treatment In Panama Working Wonders - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

29-Apr-2014

Contact: Jennifer Beal sciencenewsroom@wiley.com 44-124-377-0633 Wiley

Stem cell therapies work as a complement to standard treatments, potentially cutting the number of deaths after a year, suggests evidence from the latest Cochrane review: Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Taking stem cells from a patient's bone marrow and injecting them into their damaged heart may be an effective way to treat heart disease.

The new review, published today in The Cochrane Library, uses data involving 1,255 people from 23 randomised controlled trials, where all participants received standard treatments. Compared to standard treatment alone or with placebo, stem cell therapy using bone marrow cells resulted in fewer deaths due to heart disease and heart failure, reduced the likelihood of patients being readmitted to hospital, and improved heart function. However, researchers say that with much larger clinical trials underway, the findings are awaited to enable more certainty about the effects.

Dr Enca Martin-Rendon, author of the review, Cochrane Heart Review Group, and based at NHS Blood and Transplant and the University of Oxford, UK, said: "This is encouraging evidence that stem cell therapy has benefits for heart disease patients. However, it is generated from small studies and it is difficult to come to any concrete conclusions until larger clinical trials that look at longer- term effects are carried out."

Stem cell therapies are experimental treatments that are currently only available in facilities carrying out medical research. If eventually found to be effective, they might offer an alternative or complementary treatment to standard drug and surgical treatments for some patients with chronic heart disease. The procedure involves collecting stem cells from a patient's own blood or bone marrow and using them to repair damaged tissues in the patient's heart and arteries.

Although within the first year there were no clear benefits of stem cell therapy over standard treatment alone, when longer term data were analysed a year or more later about 3 per cent of people treated with their stem cells had died compared with 15 per cent of people in the control groups. Hospital readmissions were reduced to 2 in every 100 people compared to 9 in the control group, and adverse effects were rare.

Dr Martin-Rendon continued, "It isn't clear which types of stem cells work best or why stem cell therapies seem to work for some people but not for others. We need to find out what's different in the people who aren't responding well to these treatments as it might then be possible to tailor therapies to these patients, so that they work better."

Dr David Tovey, Editor-in-Chief, Cochrane, said: "This review should help to raise awareness of the potential of stem cell therapy to improve patient outcomes, but it also demonstrates the importance of recognising the uncertainty of initial findings and the need for further research. A Cochrane review aims to analyse all available data to give a clear picture of what the evidence shows. Ensuring health decision makers, health professionals and the general public has access to up-to-date, relevant evidence research will help to raise awareness of the effectiveness of treatments and medications and therefore improve health care."

Read the original post:
Stem cell therapies look promising for heart disease

Recommendation and review posted by Bethany Smith

Chaiwat Subprasom/Reuters/Corbis

Many companies around the world offer stem-cell treatments to patients with heart disease.

An analysis of clinical studies that use adult stem cells to treat heart disease has raised questions about the value of a therapy that many consider inappropriately hyped.

Early-phase clinical trials have reported that adult stem cells are effective in treating heart attack and heart failure, and many companies are moving quickly to tap into this potentially lucrative market. But a comprehensive study that looked at discrepancies in trials investigating treatments that use patients own stem cells, published this week in the journal BMJ (ref. 1), finds that only trials containing flaws, such as design or reporting errors, showed positive outcomes. Error-free trials showed no benefit at all.

The publication comes as two major clinical trials designed to conclusively test the treatments efficacy are recruiting thousands of patients.

The BMJ paper is concerning because the therapeutic approach is already being commercialized, argues stem-cell researcher Paolo Bianco at the Sapienza University of Rome. Premature trials can create unrealistic hopes for patients, and divert resources from the necessary basic studies we need to design more appropriate treatments.

Therapies that use adult stem cells typically involve collecting mesenchymal stem cells from bone marrow taken from the patients hip bone. The cells are then injected back into the patient, to help repair damaged tissue. Original claims that they differentiated into replacement cells have been rejected2, and many clinicians now believe that the cells act by releasing molecules that cause inflammation, with an attendant growth of oxygen-delivering small blood vessels, in the damaged tissue.

The approach has spawned international commercialization of various forms of the therapy, with companies offering treatments for disorders ranging from Parkinsons disease to heart failure. But the effectiveness of such therapies remains unproven.

I have a lot of hope for regenerative medicine, but our results make me fearful.

The BMJ study, led by cardiologist Darrel Francis at Imperial College London, examined 133 reports of 49 randomized clinical trials published up to April last year, involving the treatment of patients who had had a heart attack or heart failure. It included all accessible randomized studies, and looked for discrepancies in design, methodology and reporting of results.

Read more here:
Doubts over heart stem-cell therapy

Recommendation and review posted by Bethany Smith

Malaysia to open new budget airport in MH370 shadow

Sepang (Malaysia) (AFP) - Malaysia this week opens what it calls the world's largest airport built specifically for low-cost airlines, a project driven by budget travel's phenomenal growth but which debuts under the shadow of missing flight MH370. The $1.2 billion facility near the main Kuala Lumpur International Airport (KLIA) was originally targeted to open three years ago but has been hit by repeated delays, amid concerns over safety and subpar construction, even as costs have doubled. But the new KLIA2 budget terminal will begin operations Friday with an initial 56 flights, increasing the load as airlines move full operations over from a nearby existing facility in coming days. Its modern design features soaring ceilings, natural lighting, people-mover belts and improved connectivity with access to an existing express airport train to Kuala Lumpur 50 kilometres (31 miles) away.

Go here to read the rest:
WuXi PharmaTech Breaks Ground on New Cell Therapy Manufacturing Facility

Recommendation and review posted by Bethany Smith

New York, NY (PRWEB) April 29, 2014

The Stem Cell Institute located in Panama City, Panama, welcomes special guest speaker Roberta F. Shapiro, DO, FAAPM&R to its public seminar on umbilical cord stem cell therapy on Saturday, May 17, 2014 in New York City at the New York Hilton Midtown from 1:00 pm to 4:00 pm.

Dr. Shapiro will discuss A New York Doctors Path to Panama.

Dr. Shapiro operates a private practice for physical medicine and rehabilitation in New York City. Her primary professional activities include outpatient practice focused on comprehensive treatment of acute and chronic musculoskeletal and myofascial pain syndromes using manipulation techniques, trigger point injections, tendon injections, bursae injections, nerve and motor point blocks. Secondary work at her practice focuses on the management of pediatric onset disability.

She is the founder and president of the Dayniah Fund, a non-profit charitable foundation formed to support persons with progressive debilitating diseases who are faced with catastrophic events such as surgery or illness. The Dayniah Fund educates the public about the challenges of people with disabilities and supports research on reducing the pain and suffering caused by disabling diseases and conditions.

Dr. Shapiro serves as assistant clinical professor in the Department of Rehabilitation and Regenerative Medicine at Columbia University Medical Center.

Stem Cell Institute Speakers include:

Neil Riordan PhD Clinical Trials: Umbilical Cord Mesenchymal Stem Cell Therapy for Autism and Spinal Cord Injury

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD Stem Cell Therapy for Autoimmune Disease: MS, Rheumatoid Arthritis and Lupus

More:
Stem Cell Institute Welcomes Special Guest Speaker Roberta F. Shapiro DO, FAAPM&R to Stem Cell Therapy Public Seminar ...

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise PHILADELPHIA The University of Pennsylvanias Center for Orphan Disease Research and Therapy will host a symposium on Friday, May 2 detailing developing therapeutics for rare/orphan diseases, as well as a poster session showcasing rare disease research at the Perelman School of Medicine and The Childrens Hospital of Philadelphia. Following the Symposium, on Saturday May 3, the Center is sponsoring the Million Dollar Bike Ride for rare diseases research with a starting/finish line on the Penn Campus at 31 & Chestnut Street. The funds raised from over 350 cyclists at the Ride will be used for the rare disease grants program sponsored by the Center.

When: Friday, May 2, 2014, 8:30am 5:00pm

Where: Smilow Center for Translational Research 3400 Civic Center Boulevard Philadelphia PA, 19104

9:00 - 9:15 AM Welcome and Opening Remarks H. Lee Sweeney, PhD Director, Center for Orphan Disease Research and Therapy 9:15 - 10:00 AM Emil D. Kakkis, MD, PhD Chief Executive Officer and President of Ultragenyx Pharmaceutical, Inc. Improving the Process of Rare Disease Treatment Development 10:00 - 10:45 AM Jerry R. Mendell, MD Director, Center for Gene Therapy, The Research Institute at Nationwide Childrens Hospital Progress Toward Molecular Based Therapies for Neuromuscular Disease 10:45 - 11:00 AM BREAK 11:00 - 11:45 PM Forbes D. Porter, MD, PhD Senior Investigator, Program Head and Clinical Director, NICHD, NIH Development of a 2-hydroxypropyl--cyclodextrin therapeutic trial for Niemann-Pick disease, type C1 11:45 - 12:30 PM Akshay K. Vaishnaw, MD, PhD Executive Vice-President & Chief Medical Officer, Alnylam Pharmaceuticals Inc. Development of a Novel RNAi Therapeutic, Patisiran, for the Treatment of TTRmediated Familial Amyloidotic Polyneuropathy (FAP) 12:30 - 2:00 PM LUNCH 2:00 - 2:45 PM Gwyneth Jane Farrar, PhD Professor of Genetics, Smurfit Institute of Genetics, School of Genetics and Microbiology, Trinity College Dublin, Ireland Exploration of AAV-Mediated Gene therapies for Inherited Ocular Disorders 2:45- 3:30 PM Edward G.D. Tuddenham MD Emeritus Professor of Haemophilia UCL Katharine Dormandy Haemophilia Centre, Royal Free Hospital "Gene Therapy for Haemophilia B - UCL/St Jude's Trial Update at 4 Years" Agenda and other details can be found on the Center for Orphan Disease Research and Therapy site. Register for this free symposium here.

### Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise. The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year. The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine. Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.

View post:
International Rare Disease Symposium Brings Together Academia, Industry, and Government at Penn Medicine

Recommendation and review posted by Bethany Smith

Porn, Ellen Page, Genetics, and Abortion
This is truly an aimless video, so...yeah take it as you will. - - - homosexuality and genes (I touch upon this a little bit so might as well include a link)...

By: Unworshipediety

Read the rest here:
Porn, Ellen Page, Genetics, and Abortion - Video

Recommendation and review posted by Bethany Smith

Rockville, MD (PRWEB) April 30, 2014

OriGene Technologies (Rockville, MD), the industrys largest supplier of gene-centric research tools, launches a new product line of gene-knockout kits using CRISPR technologies. The new products provide a complete solution for researchers to knock out a human gene at the chromosomal level. This genome wide offering provides an unprecedented convenience for genome editing using the CRISPR technology.

OriGene has always been focused on providing state-of-art reagents of highest quality. Its comprehensive offering of expression cDNA clones, shRNA/siRNA, recombinant proteins and antibodies are widely utilized in the biomedical research community world-wide and are cited in thousands of publications.

CRISPR is a revolutionary tool for biomedical scientists. Our dream of a pair of simple accurate molecular scissor is now a reality. As the worlds largest supplier of molecular tools, OriGene is excited to be in the middle of this technology boom. Launching genome-wide knock-out kits is only the very first step for OriGene to help harness the power of the CRISPR technology, said Dr. Wei-Wu He, Ph.D., CEO and Chairman of OriGene.

An established leader in the molecular biology market, especially utilizing its US-based gene-synthesis capacity, OriGene is in a perfect position to provide genome wide CRISPR tools to the research community, remarked Dr. Youmin Shu, SVP of Molecular Biology. We provide a kit against every human gene locus, containing 2 gRNAs and a compatible donor vector with a functional cassette. In additional to gene knockout, this kit can also be used for promoter strength study for each gene locus. The pre-designed nature of the kit greatly reduces the researchers time and effort using this great platform.

Additional information about OriGene Technologies and CRISPR product line is available at http://www.origene.com/CRISPR-CAS9/.

About OriGene Technologies: OriGene Technologies, Inc., is a gene centric life sciences company dedicated to support academic, pharmaceutical and biotech companies in their research of gene functions and drug discovery. OriGene's novel product line includes the world's largest cDNA and shRNA clone collections, over 10,000 purified human proteins from mammalian cells, high quality monoclonal antibodies (TrueMAB) against full-length proteins for native epitopes, 100,000 highly validated human tissues, and protein microarray products and services. For more information, visit http://www.origene.com.

For inquiries, please contact: Dr. Youmin Shu, SVP, OriGene Technologies, Inc. Tel: (301) 340-3188

More:
OriGene Launches Genome-wide Gene-knockout Kits Using CRISPR Platform

Recommendation and review posted by Bethany Smith

Plant physiologist Stefano Pietra shows in his doctoral thesis that the SABRE gene is necessary for plants to coordinate the polarity of their cells. The gene "tells" all cells in a certain region what is up and what is down and how they should modify their form accordingly.

Plant cell growth is often coordinated within a tissue layer, a concept that researchers name planar polarity.

"How cells within a large area all get the information to orient in a similar way is still not entirely clear, but my research identifies a new player that is involved in this process, the SABRE gene," says Stefano Pietra.

He has analysed the position of small hairs on root cells of the model plant Arabidopsis thaliana, a small weed. These hairs grow with a specific orientation -- similar to those on the skin of animals and men that all point in the same direction. Hair orientation is very easy to observe, and the analysis gives insight on the mechanisms coordinating cell polarity in other parts of the organism.

In addition to coordinating the polarity of cells, Stefano Pietra also shows thatSABRE makes sure that cells divide neatly and form long straight files that align to the direction of root growth. If the SABRE gene is not functional, cell divisions are not perpendicular to the root growth direction, cell files are not straight, and the overall root morphology is affected.

Another role of SABRE is to stabilize patterning of the root surface, which is the coordinated decision of all cells in a file to either grow a hair or not. This selection is driven by the mechanisms that control how initially identical cells differentiate and acquire specific shapes and functions, an essential process in all multicellular organisms.

The exact way in which SABRE performs its functions is still unclear, but Stefano Pietra has discovered that the gene has an effect on the organization of the plant cytoskeleton, a scaffolding of small and very dynamic filaments and tubules that controls many cellular processes including shape acquisition and growth. Organization of the cytoskeleton could therefore be important in plants for coordinating the polarity of cells and the specification of their fate.

Not only plants, but also animals and humans need mechanisms to orient their cells and to tell them in which direction they should grow; when these mechanisms do not work the organisms have serious problems to develop and often die prematurely.

Genes similar to SABRE are present in many species, including men, but their function is still unknown.

"Having found one function of SABRE in plants, my research could help studying similar genes in other species. My study also opens the way for future studies on the role of the cytoskeleton and the exact relationship between SABRE and the cytoskeleton."

More here:
Gene that helps plant cells finding right direction

Recommendation and review posted by Bethany Smith